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Available online 18 August 2016Introduction: To evaluate the usefulness of in silico assay in predicting drug-induced QTc prolongation and ven-
tricular proarrhythmia, we describe in this study 2-dimensional transmural ventricular wedge preparation
model (2D model) of non-failing (non-FH) and failing hearts (FH) based on O'Hara-Rudy dynamic model of
human ventricular myocytes.
Methods: Using the prepared 2D model, we simulated ventricular action potential and recorded electrocardio-
gram for the non-FH and FH. The FH model was constructed based on differences in mRNA, protein, and/or cur-
rent levels of ion channels between non-diseased heart and failing heart. To simulate the effects of selected drugs,
we incorporated changes in ion channel conductance depending on the IC50 value andHill coefﬁcient at unbound
drug blood concentrations.
Results: Dofetilide concentration-dependently induced QTc prolongation at therapeutic concentration in the 2D
model of both non-FH and FH. The QTc prolongation in FH was longer than that in non-FH. These ﬁndings are
consistent with previously reported clinical data. At supratherapeutic concentration 20 nM, dofetilide induced
Torsade de Pointes-like arrhythmia in the 2D non-FH model. In contrast, the single ventricular myocyte model
did not quantitatively reproduce experimental data due to lack of electrotonic interaction. The simulated QTc
change induced by six drugs examined in the IQ-CSRC prospective study was almost equivalent to that recorded
in drug-treated healthy volunteers.
Discussion: Our 2Dmodel with or without heart failure faithfully reproduced drug-induced QT prolongation and
ventricular arrhythmias, suggesting that the in silico approach is a powerful tool for predicting cardiac safety of
drug candidates at preclinical stage.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
Current approaches for evaluation of preclinical drug candidates' po-
tential for delayed ventricular repolarization are based on ICH, S7B
guidelines, which require performance of both hERG current assay and
in vivo QT assay for drugs in preclinical stage and QTc prolongation
test for drugs in clinical development. However, it has recently been
suggested that such approaches are inadequate for predicting drug can-
didates’ potential for proarrhythmia. Accordingly, the Comprehensive in
vitro Proarrhythmia Assay (CiPA) has been proposed as a novel strategy
intended to replace the guidelines with a multi-channel assay, in silico
assay, and a myocyte assay that uses human induced pluripotent stem
cell-derived cardiomyocytes (Cavero & Holzgrefe, 2014; Colatsky et al.,
2016).
Among these assays, the in silico assay of human ventricular action
potential (AP) is expected to be one of the most useful tools forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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human cardiac currents. Indeed, the O'Hara-Rudy dynamic (ORd)
human ventricular AP model, which was constructed based on data
from over 100 non-diseased human ventricles, is currently believed to
be themost suitablemodel for simulations of ventricular proarrhythmia
(O'Hara et al., 2011; Pugsley et al., 2014). Mirams et al. (2014) also re-
ported that AP simulation can be a useful tool for predicting drugs car-
diac safety and provided a web portal for in silico AP prediction using
various human and animal ventricular AP models (Williams &
Mirams, 2015). On the other hand, it has been reported that there are
measurable differences in AP upstrokes between simulation of a single
ventricular myocyte (VM) at the cellular level (0D) and simulation at
tissue level (Elshrif, Pengcheng, & Cherry, 2014), with tissue level simu-
lation being a more useful approach for predicting drug safety in the
human heart. Indeed, several tissue simulation studies aimed at
predicting drug effects on ECG have recently been reported. Polak et
al., for instance, evaluated QTc changes following administration of an-
tipsychotic drugs and Quinidine using a transmural 1-dimensional
(1D) model based on ten Tusscher (tT) and ORd membrane kinetics
(Glinka & Polak, 2014; Polak, 2013). Moreno et al. (2011), on the
other hand, predicted drug effects on reentry induction in 1D and 3-di-
mensional (3D) ventricularmodels based on tTmembrane kinetics, and
indicated differences in reentry inducibility between the failing heart
(FH) and non-FH. Okada et al. (2015) also numerically evaluated
drug-induced arrhythmia using an integrated 3D ventricular model.
The usefulness of ECG simulation for evaluation of drug safety will be
probably discussed in future reports.
Current approaches for evaluation of drug safety focus only on non-
diseased state, because it is still very difﬁcult to predict drug effects in
diseased state using conventional pharmacological tests. In silico assay
would be the only ethical technique that can help predict drug safety.
Using differences in ion channel function between FH and non-FH,
Elshrif et al. (2014) reported new AP models of FH based on ORd and
Priebe-Beuckelmann human ventricular models (Priebe &
Beuckelmann, 1998). In another study using transmural FH 1D model,
Gomez et al. (2014) reported that both increase in electrophysiological
gradient and reduction in electrical propagation result in
proarrhythmia. However, no report has so far compared simulated
ECG and clinical ECG in patients with FH. In addition, no report has sim-
ulated drug effects on ECG in patients with FH.
Previously, we reported the preparation of a 2D transmural ventric-
ular wedge model (2D model) of non-FH and FH based on the ORd
model (Kubo et al., 2015). Here, we evaluated the usefulness of this
model in predicting drug-induced proarrhythmia in preclinical studies
and showpossiblemechanismof Torsade de Pointes (TdP)-like arrhyth-
mia induced by dofetilide. Dofetilide, a major IKr blocker, was used as
positive control. To validate the 2D model, we evaluated selected
drugs effects on QTc in simulated human ECG and compared the results
to clinical data reported in the IQ-CSRC prospective study. The IQ-CSRC
prospective study as performed by Darpo et al. (2015), is considered as
an appropriately designed, well executed study equivalent to a formal
Thorough QT (TQT) study.
2. Methods
2.1. Computer simulation
Based on the ORd model, we simulated selected drug effects on AP
and ECG in the 0D model (single myocyte) and in the bidomain 2D
wedge preparation model (4.5 cm in length and 1.01 cm in thickness).
The 2D non-FHmodel was paced from a section of the endocardial bor-
der (1.1 cm in length), therebymimicking transmural propagation dur-
ing sinus rhythm within the ventricular free wall. To obtain ventricular
transmural gradient, endocardial (Endo), midmyocardial (M), and epi-
cardial (Epi) layers with a thickness of 0.12 cm, 0.65 cm, and 0.24 cm,
respectively (Fig. 1A) were selected. As modiﬁcation of the ORd modelis also required to construct a tissue model (O'Hara et al., 2011), INaF
was ampliﬁed to adjust conduction velocity (CV) of the 2D model to
clinical values (Taggart et al., 2000). A 2-ms pacing stimuli with a
strength twice the diastolic thresholdwas trans-membranously applied
to the endocardial end at a pacing cycle length (PCL) of 500, 1000, 2000,
and 4000ms. To obtain an ECG similar to that of the left precordial ECG,
a unipolar recording electrode was applied 2.6 cm above the epicardial
end of the tissue. To achieve transmural difference in CV, ﬁber orienta-
tion of the vertical cross-section of 3D rotational anisotropy was incor-
porated in the system (Ashihara et al., 2003). Other model
parameters, such as tissue conductivity and boundary conditions,
were selected as described elsewhere (Ashihara & Trayanova, 2004).
We also simulated excitation propagation in tissue using imaging of
membrane potential. To construct the FH model, we ﬁrst referred to
the data provided in the original ORd model, because the non-FH
model used in this study is mainly based on the ORd model. O'Hara et
al. (2011) selected reliable literature to reproduce human ventricular
AP, and the ORd model is currently believed to be the most suitable
model for simulation of ventricular proarrhythmia. We referred the
work published by Soltysinska et al. (2009), which includes a compari-
son of mRNA level between non-FH and FH. With this bottom-up ap-
proach, we added a “top-down” approach based on clinical ECG data
for FH to reproduce a FH condition (Khan et al., 2007). Finally, we con-
sidered published data on current density and membrane capacitance
to ﬁt clinical papers (Beuckelmann et al, 1993; Konarzewska et al.,
1995; Nabauer et al, 1996; Schwinger et al, 1999; Valdivia et al.,
2005), because some of the parameters could not be determined from
mRNA change. For example, INaF and INaL current amplitudes could not
be determined frommRNA level. Current amplitude, protein expression
andm-RNA level for all ion channels, exchangers, and VMcapacitance of
FH patient (Fig. 2) as well as differences in all parameters between non-
FH and FH are shown in Supplementary Table 1. Computation was per-
formed on a linux workstation and a laptop computer using a program
coded by the “C” language.
2.2. Simulation experimental and clinical data
To simulate the effects of selecteddrugs, each ion channel conductance
was changed depending on the IC50 value and Hill coefﬁcient (nH) at un-
bound blood concentration. Dofetilide IC50 value for IKr (9.76 nM) andHill
coefﬁcient (0.89) by conventional patch clamp system at physiological
temperature were obtained from the literature (Du, El Harchi, Zhang,
Orchard, & Hancox, 2011). Dofetilide protein binding rate (64%) and clin-
ical ECG data were obtained from the literature (Pﬁzer Labs, 1999;
Sedgwick, Rasmussen, Walker, & Cobbe, 1991). Experimental data for
simulated drugs, Dofetilide (CID: 71329), Hydrodolasetron (CID:
52950077), Levocetirizine (CID: 1549000), Moxiﬂoxacin (CID: 152946),
Ondansetron (CID: 4595), and Quinine (CID: 3034034), were shown in
the Table 1. Clinical data of QTc change were those published in the IQ-
CSRC prospective study (Darpo et al., 2015).
2.3. Simulation condition and data analysis
The effects of dofetilide on APwere simulated at 5, 10, 15, 20, 25, 30,
40, 50, 100, 200 and 300 nM in the 0Dmodel. The shape and duration of
the simulated AP were determined as early afterdepolarization (EAD),
AP duration (APD) at 90% repolarization (APD90), and APD90 minus
APD at 30% repolarization (APD30–90). The effects of dofetilide on ECG
were simulated at 0.5, 1.0, 1.5, 2.0, 3.0, and 4.0 ng/mL to predict QT pro-
longation, and at 5, 10, 15, 20, 25, and 30 nM to evaluate threshold con-
centrations for proarrhythmia. The effects of six drugs reported in the
IQ-CSRC prospective study onQTcwere simulated atwide range of plas-
ma concentrations including supratherapeutic concentration. QRS dura-
tion, QT interval, and Tpeak-to-end (Tpe) were measured based on the
simulated ECG. QT interval was determined by Fridericia's formula
(QTc = QT / RR1/3).
Fig. 1. (A) Schematic representation of the in silico 2Dmodel of transmural ventricularwedge preparation. (B) Simulated ECG and AP in the 0D and 2Dmodels of the non-FH and FH at PCL
1000 ms. The black solid and gray dashed lines represent simulated ECG of the FH and non-FH in the right panel, respectively. Green, blue, and red lines indicate AP in Endo, M, and Epi
layers, respectively. Endo, M, and Epi denote endocardial, midcardial and epicardial layers, respectively. The excitation propagation in the non-FH and FH 2D models are shown in
Supplementary movie 1.
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3.1. AP in the 0D model
Simulated AP in the non-FH and FH 0Dmodels is shown in Fig. 1B. In
the non-FHmodel, APD90 for Endo,M, and Epi at PCL 1000mswere 252,
336, and 226ms, respectively. In contrast, APD90 for Endo, M, and Epi in
the FH model were 72, 32, and 86 ms longer than those in the non-FH
model, respectively. Similarly, APD30–90 for Endo, M, and Epi in the FH
model were 38, 29, and 55 ms longer than those in the non-FH model,
respectively, resulting in a triangular AP form in the FHmodel. AP trian-
gulation, as assessed by prolongation of repolarization time from
APD30–90, is reported as one of the proarrhythmic predictors of 20 se-
lected compounds (Hondeghem, Carlsson, & Duker, 2001).
Changes in each parameter in the 0D model are shown in Fig. 3. In
the FHmodel, INaF, L-type Ca2+ current (ICaL), intracellular Ca2+ concen-
tration ([Ca2+]i), Na+/K+ pump current (INaK), SR Ca2+ release ﬂux viaRyanodine receptor (Irel), Ca2+ uptake via SERCApump (Iup), and potas-
sium currents of the rapid and slow delayed rectiﬁer (IKr and IKs), in-
ward rectiﬁer (IK1), and transient outward (Ito) decreased compared
to the corresponding values in the non-FH model. On the other hand,
late component of Na+ current (INaL) and Na+/Ca2+ exchange current
(INaCa) increased in the FH model compared to those in the non-FH
model. These differences between the non-FH (blue dashed lines) and
FH (red dashed lines) in the 0D model were also evident in the 2D
model.
3.2. Effects of dofetilide on AP
Consistent with the previous study by Guo et al. (2011), dofetilide
induced EAD at 100 nM in the non-FH model in our study (Fig. 4A,
green dashed lines). On the other hand, in the FH model, dofetilide in-
duced EAD at 25 nM (Fig. 4A, orange dashed lines). The threshold con-
centration for EAD induction in the FH model was 4 times more
Fig. 2.Modiﬁed parameters in the in silico FHmodel based on human experimental data for the non-FH and FH. (A) Ratio of data obtained in the FHmodel to those obtained in the non-FH
for current density, protein expression, and capacitance. Non-FH and FH are represented by green and orange ﬁlled bars. Experimental data for non-FH and FH are represented by black
open and gray ﬁlled bars (Beuckelmann et al., 1993; Konarzewska et al., 1995; Nabauer et al., 1996; Schwinger et al., 1999; Valdivia et al., 2005). (B) Ratio of data obtained in the FHmodel
to those in the non-FH for Endo, and M or Epi to Endo inmRNA level of cardiac current in the case of simulation and for experimental data (Soltysinska et al., 2009). The black horizontal,
backslash, and vertical lines represent experimental ratio of Endo,M, and Epi respectively. The orange, horizontal, backslash, and vertical lines represent simulated ratio of Endo,M, and Epi
respectively. Details of the parameters for the non-FH and FH are shown in Supplementary Table1.
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in control VM in the experimental study by Guo et al. (Fig. 4B, black
open square) was considerably longer than APD90 (~439ms) in normal
human ventricular wall (Drouin, Charpentier, Gauthier, Laurent, &Marec, 1995). In another experiment using human papillary muscle,
Barandi et al. (2010) reported that APD90 in the control (black open cir-
cles) was in the physiological range of human VMs. In our study, the
simulated APD90 in the non-FH model at PCL 500, 1000, 2000, and
Table 1
Experimental data for drugs simulation.
Drugs MW Current IC50
μM
nH Protein binding
%
Reference
Dofetilide 441.6 IKr 0.00976 0.89 64 Du et al. (2011)
Pﬁzer Labs (1999)
Hydrodolasetron 326.4 IKr 12.1 1a,* 75 Li et al. (2009)
Berry, Li, and Zhao (2011)
Levocetirizine 388.9 IKr N30 (30⁎) 1a,* 96.1 UCB Labs. (2007)
Bree et al. (2002)
Moxiﬂoxacin 401.4 IKr
IKs
INaL
93.041
50.321
382.337
0.6
1
1.1
39.4 Stass and Kubitza (1999)
Kramer et al. (2013)
Ondansetron 293.4 IKr
ICa
INaL
1.492
22.551
19.181
1
0.8
1
88.2 Hallifax et al. (1992)
Kramer et al. (2013)
Quinine 324.4 IKr
IKs
Ito
INaF
INaL
Ica
5.17
37.453
79.254
24.151
11.053
27.178
1
1.1
1
1.1
0.4
1
92.5 Mihaly et al., (1987)
Kramer et al. (2013)
a No data has been reported.
⁎ Used value for calculation.
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Barandi et al. (2010) in human papillary muscle, 224, 252, 277, and
299 ms, respectively. However, the prolongation of APD90 induced by
dofetilide (50 nM) in the non-FHmodel (green ﬁlled triangles)was lon-
ger than that in the reported experimental data (black ﬁlled circles).
Simulations of APD90 in the FHmodel (orange open triangles) were lon-
ger than those in the non-FH model (green open triangles).
3.3. Construction of the 2D model of non-FH and FH
Excitation propagation was simulated in the 2D model, and AP was
recorded from the Endo,M, and Epi layers. As shown inmiddle and bot-
tom panels of Fig. 1B, AP forms in the 2D model were different from
those in the 0D model. It is noteworthy that APDs in the 2D model
were slightly longer than those in the 0D model. The increase in
APD90 in the non-FH and FH 2Dmodels was 88 and 96ms, respectively
in the Endo layer, 22 and 55 ms, respectively in theM layer, and 84 and
95 ms, respectively in the Epi layer. APD prolongation in the 2D model
might have resulted from electrotonic interaction among VMs, which
was not taken into account in the 0Dmodel. As shown in Fig. 5, the sim-
ulated ECG in the non-FH 2D model showed physiological ranges of QT
interval, Tpe, QRS duration, and CV (Hakacova, Robinson, Olson,
Selvester, & Wagner, 2008; Hakacova et al., 2010; Nakagawa et al.,
2004; Taggart et al., 2000). On the other hand, the simulated ECG in
the FH 2D model showed longer QRS duration, which reﬂects slower
CV, longer QT interval, and lower T-wave amplitude, compared to the
non-FH 2D model (Fig. 1B, top panel). As shown in Fig. 5E, such slower
CV was faithfully reproduced in the FH model as reported in patients
with coronary artery disease (Taggart et al., 2000). Imaging of excitation
propagation in the non-FH and FH 2Dmodels also revealed these differ-
ences (Supplementary movie 1).
3.4. QT prolongation and Torsade de Pointes (TdP)-like arrhythmia induc-
tion by dofetilide in the 2D model
Next, we simulated the effects of dofetilide on ECG in the non-FH
and FH 2D models. As shown in Fig. 6A and B, dofetilide dose-depen-
dently prolonged QTc interval in both the non-FH and FH models. This
prolongationwas quantitatively similar to that reported in clinical stud-
ies by Pﬁzer Labs (1999) and Sedgwick et al. (1991), respectively.
Dofetilide at its therapeutic concentration (2 nM) prolongedQT interval
by 34 and 54 ms in the non-FH and FH models, respectively. At its
supratherapeutic proarrhythmic concentration (20 nM), dofetilideinduced arrhythmia in the 2D non-FH model at PCL 1000 ms (Fig. 6C).
This concentrationwas 2 times higher concentration atwhich dofetilide in-
ducedEAD in theMcell 0Dmodel (Table 2). The threshold concentrationof
dofetilide forEADandproarrhythmiavariedbetweenPCLandphysiological
conditions, and the threshold concentration in M was lower than that in
Endo or Epi in the 0Dmodel (Table 2). Interestingly, the threshold concen-
trations of dofetilide for proarrhythmia in the 2D model was higher than
that for EAD induction in the 0Dmodel in both the non-FH and FH. Tissue
imaging of the 2Dmodel revealed the largely-meandering functional reen-
try,which is similar to the characteristic featureof TdP (Fig. 6D, Supplemen-
tary movie 2). The membrane potential imaging of arrhythmia in the 2D
model also revealed that the original induction point of EAD by dofetilide
was in Endo to M layer, not in M layer.
3.5. Differential effects of dofetilide on QTc, APD90, APD90 dispersion in the
0D and 2D models
The prolongation of QT interval in the FH model in response
to dofetilide was greater than that in the non-FH model (Figs. 6B
and 7A), yet a similar threshold for proarrhythmia (Table 2). To clarify
the reason of the unchanged proarrhythmia threshold under the FH
condition, we evaluated the effect of dofetilide on QTc, APD90 and
APD90 dispersion in the non-FH and FH models (Fig. 7). Interestingly,
APD90 change by dofetilide in Endo was greater than that in M in the
2D model, which was different from the results in the 0D model
(Fig. 7B and C). In addition, the APD90 change by dofetilide in the 2D
model was greater than that in the 0D model. As shown in Fig. 7D and
E, APD90 dispersion in the non-FH model was greater than that in the
FH model.
3.6. Simulation of IQ-CSRC prospective study using 2D model
To validate the 2D model, we tried to reproduce the results of IQ-
CSRC prospective study (Fig. 8). The simulated QTc change induced by
ﬁve QT-positive drugs reproduced positive slope of the concentration/
QTc relationship. The simulated QTc change induced by dofetilide and
ondansetron was consistent with clinical ﬁndings in drug-treated
healthy volunteers (Fig. 8A and B). Quinine and Moxiﬂoxacin caused a
muchpronouncedQTc change than clinically reported, although the dif-
ferences were not signiﬁcant at low therapeutic plasma concentration
(Fig. 8C and D). Hydrodolasetron, on the other hand, produced shorter
QTc prolongation (b10 ms) that clinically reported (Fig. 8E). Finally,
the QT-negative drug, levocetirizine, did not prolong QTc at
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Fig. 3. Traces of AP, primary transmembrane currents, Ca2+ transient, and Ca2+ release and uptake currents in the sarcoplasmic reticulum of Epi at PCL 1000ms in the 0D and 2Dmodels.
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CSRC prospective study (Fig. 8F).
4. Discussion
According to current ICH, S7B guideline, the preclinical testing strat-
egy describes the use of only healthy animals, even though the drug
candidates have to be administered to patients with various risks for le-
thal arrhythmia. Cardiovascular Safety Outcome Trials Think Tank
discussed how likely it is that a possible signal indicating risk is real,
based on strength of evidence of arrhythmia induction (Sager et al.,
2015). To predict preclinical drug candidates' cardiac safety, we con-
structed a 2D transmural ventricular wedge preparation model of
non-FH and FH and used these models together with the VM model,
which is now the focus in CiPA (Cavero & Holzgrefe, 2014; Colatsky et
al., 2016). Dofetilide was selected as a positive control to simulate the
effects of drugs on patients with or without heart disease. The effects
of dofetilide are supported by a number of experimental reports(Beuckelmann et al., 1993; Nabauer et al., 1996; Schwinger et al.,
1999; Soltysinska et al., 2009; Valdivia et al., 2005).We also reproduced
the results of the IQ-CSRC study, which is designed to generate ECGdata
with the same high level of conﬁdence as a TQT study. The selected six
marketed drugs are well known for their QT effect on human.
4.1. Necessity for tissue level in silico assessment of drug candidates’ cardiac
safety
The differences in AP forms between the 0D and 2Dmodels in Fig. 1B
suggest that an intercellular electrophysiological connection among
VMs is necessary for simulation of drug effects in living organs. The ef-
fects of dofetilide on APD at the cellular level were overestimated (Fig.
4B), but the effects on QTc in both the non-FH and FHmodels correlated
well with clinical reports (Fig. 6B). In addition, the simulated QTc
change induced by the six selected drugs in the IQ-CSRC prospective
study was almost equivalent to clinical ﬁndings in drug-treated healthy
volunteers (Fig. 8). Considering the consistency in QTc results between
Non-FH (Control) 
FH (Control)
FH (Dofetilide 25 nM)
Non-FH (Dofetilide 100 nM)
Cycle Length : 
        4000 ms
A B
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Fig. 4. Simulation of the effects of dofetilide on APs of Endo in 0Dmodel. (A) Simulation of the effects of dofetilide on AP. The solid and dashed green lines represent control and 100 nM
dofetilide in the non-FH 0Dmodel, respectively. The solid and dashed orange lines represent control and 25 nM dofetilide in the FH 0D model, respectively. (B) APD90 as function of PCL
following administration of dofetilide or control in the simulation in the non-FH and FH 0D model. Experimental data from human ventricular cells by Guo et al. (2011) for control and
100 nM dofetilide are represented by black open and black ﬁlled square, and from human papillary muscle by Barandi et al. (2010) for control and 50 nM dofetilide are represented by
black open and black ﬁlled circles, respectively. Simulated data for control, 50 and 100 nM dofetilide in non-FH are represented by green open, green ﬁlled, blue ﬁlled triangles,
respectively. Simulated data for control in FH is indicated by orange open triangles.
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ulation is more than just useful for assessing drug candidates’ cardiac
safety because the 2D model better emulated clinical response com-
pared to single cell 0D model. There are in fact 3 reasons that highlight
the need for tissue level in silico approach in the assessment of drug can-
didates’ cardiac safety. 1 - The electrotonic interaction among VMs
might modify drugs pharmacological effects. 2 - Isolation of human
VMs itself might damage the electrophysiological properties of human
VMs, leading to physiological conditions different from those in healthy
organs. 3 - Drug pharmacokinetic parameters in isolated VMs might be
different from those in living organs due to the difference between
physiological condition in the body and in vitro experiments. Indeed,
under physiological conditions, the drug reaches ventricular cells via
blood circulation as oppose to extracellular reperfusion in in vitro
experiments.
Simulation using the 1D model as reported by Elshrif and Cherry
(2014) shows decreased AP upstroke due to electrotonic effect, al-
though no remarkable change in APD was observed as compared to
the 0D model. However, we showed in this study marked changes in
AP shape covering both upstroke and APD in the non-FH and FH 2D
models (Fig. 1B). These different results suggest a certain difference be-
tween the 1D and 2D models. This is because AP in the 2D model is
transmurally affected not only by VMs in other myocardial layers, but
also by VMs in the same layer. In addition, and as shown in Fig. 1B, the
difference in APD and AP shape between the 0D and 2D models in the
non-FH model was larger than that in the FH model, even within the
common 2D structure of the non-FH model. These results indicate that
the electrotonic effect in the 2D model readily varies depending on
VMs (Fig. 1B, right panel). At the tissue level, the ultimate model
would be awhole heart 3Dmodel; however, such hugemodelwould re-
quire a supercomputer, and thus, enormous cost making cost effective-
ness unmanageable. Therefore, the use of our 2D model of transmural
ventricular wedge preparation with a personal computer would be the
most cost effective approach for evaluating preclinical drug candidates’
cardiac safety.
4.2. Characteristics of the FH in the 0D and 2D models
Although there are reports on 0Dmodelwith FH (Elshrif et al., 2014;
Gomez et al., 2014), there is as far aswe knowno study that used tissue-
level simulation to predict drug effects in FH. The importance of evalu-
ation of drug safety under diseased conditions is not a focus ofregulatory requirements. However, we believe that in silico model
under diseased conditions is useful, because drugs can be used in pa-
tients with various risks of lethal arrhythmia. In the present study, we
constructed a FH 2D model based on the changes that occur in patients
with FH, i.e. changes in m-RNA, proteins expression, and current levels
of each cardiac ion channel. Our results show that simulated ECG in
the FH had wider QRS complex, longer QT interval, and lower T-wave
amplitude compared to the non-FH (Fig. 1B). These ﬁndings are consis-
tent with ECG changes observed in human FH (Khan et al., 2007). In ad-
dition, we found that dofetilidemarked QTc prolongation in the FH (Fig.
6B), which is consistent with the results of previous clinical data in pa-
tients with ischemic heart failure (Sedgwick et al., 1991). These ﬁndings
suggest that in silico 2Dmodel of FHwould be useful for evaluating drug
safety under FH conditions.
As for the 0D model of FH, triangulation of AP (Fig. 1B) was also ob-
served in a similar model reported by Elshrif et al. (2014). However,
there are marked difference in Ca2+ dynamics between the study by
Elshrif et al. (2014) and the present study. We found that ICaL and
[Ca2+]i were slightly decreased in both the 0D and 2D models of FH
(Fig. 3), which denoted the same tendency of previous experimental re-
ports summarized by Elshrif et al. (2014). On the other hand, Elshrif et
al. reported that ICaL was almost twice larger in the FH model than in
the experimental data. These differences could be mainly explained by
the use of different references in the construction of the FH model:
Whereas Elshrif et al. referred to average change in previous human
and animal FH studies, we referred to only typical references on the
FH, mainly those based on ORd model as a bottom-up approach. In the
present study, our FH model could reproduce the effects of dofetilide
in patients with ischemic heart failure, indicating that model reliably
represents a human FH condition.
4.3. TdP-like arrhythmia and EAD induction for prediction of drug safety
and possible mechanism of TdP
Among Endo, M, and Epi in the non-FH and FH 0Dmodel, we found
large differences in threshold concentration for dofetilide EAD induction
(Table 2). In addition, the single cell models suggest a lower threshold
for EAD induction by dofetilide in FH compared to non-FH, but in the
2D model the proarrhythmia risk thresholds are comparable for FH
and non-FH. As for the accuracy of the FH model for evaluating
proarrhythmia risk threshold, it is believed that this model is adequate
as a typical FH model based on our pathological validation in this
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tween FH and non-FH in human even if in vitro experimental data from
single human cell showed different EAD threshold between non-FH and
FH, because isolated ventricularmyocytes have also different properties
from living organ. These differences highlight the importance of tissue
model for predicting drug proarrhythmia.Wemay need to consider ad-
ditional pathophysiological factors, including the stages of heart failure
and hypokalemia to simulate various FH conditions, and a large impact
on the model results by differing parameterization of FH model.
Interestingly, dofetilide quantitatively prolonged QTc intervals in
both the non-FH and FH 2D models, and QTc prolongation under the
FH condition was larger than that under the non-FH, in spite of equal
proarrhythmic threshold (Fig. 6B). Thus, dofetilide greater prolongation
of QT interval in FH as compared to non-FH, yet a similar threshold for
proarrhythmia under both conditions, appears to reﬂect the shortcoming
of QT prolongation as a biomarker for proarrhythmic risk. It therefore
seems that the magnitude of QT prolongation is not necessarily and suf-
ﬁcient proportional to proarrhythmic risk. Needless to say that APD pro-
longation together with AP triangulation shape, cannot be an accurate
bio-marker for predicting drug induced arrhythmia. The possible expla-
nation for comparable threshold arrhythmia between the non-FH andFH is as follows: It is generally thought that prolongation of QT interval
is proarrhythmic, while reduction in repolarization dispersion is antiar-
rhythmic. In the present study, the FHmodel showed longer QT interval
(proarrhythmic, Fig. 7A) with less repolarization dispersion (antiar-
rhythmic, Fig. 7D) than the non-FHmodel, suggesting that the latter an-
tiarrhythmic effect offset the former proarrhythmic effect. This may
explain the unchanged proarrhythmia threshold under the FH condition.
Interestingly, the membrane potential imaging of arrhythmia in the 2D
model also revealed that the original induction point of EAD by dofetilide
was in Endo toM layer, not inM layer (Fig. 6D, Supplementarymovie 2).
In the 2Dmodel, the prolongation of APD90 in Endobydofetilidewas lon-
ger than that in M, which are different from the results in the 0D model
(Fig. 7B, and C). Therefore, the electrotonic interaction among VMs
changes the effects of dofetilide onAPD90 prolongation and the inducibil-
ity of EAD in VMs. These results indicate that the electrotonic effect in tis-
sue is an essential factor to predict drug effects on living organ.
The results of this study also suggest that EAD without TdP is not an
indicator for arrhythmia in living organs and that evaluation of drug-in-
duced TdPwith EAD is necessary for drug safety evaluation. Indeed, it is
usually thought that EAD or EAD-like activation at tissue level typically
results in premature ventricular contraction (PVC). From this viewpoint,
Fig. 6. (A) Simulation of ECG following treatmentwith dofetilide in thenon-FH and FH2Dmodels at PCL 1000ms. (B) SimulatedQTc change following treatmentwith dofetilide in the non-
FH (greenﬁlled circles) and FH (orange ﬁlled circles). For comparison, data fromhealthy volunteer (black open circles) by Pﬁzer Labs (1999) and patientwith ischemic heart failure (black
ﬁlled circles) by Sedgwick et al. (1991) are plotted. (C) Simulated ECGs andAP following treatmentwith dofetilide (20nM) in thenon-FH. (D) Consecutive snapshots of dofetilide (20 nM)-
induced arrhythmia in the non-FH. The colour bar provides a colour distribution of the membrane potential in mV.*; EAD induction, †; direction of wave-front propagation. Details of
arrhythmia induction are shown in Supplementary movie 2.
Table 2
Threshold concentration for EAD and proarrhythmia induced by dofetilide.
0D model 2D model
Threshold for EAD
induction (nM)
Threshold for proarrhythmia (nM)
Condition PCL
(ms)
Endo M Epi
Non-FH 1000 300 10 300 20
4000 100 15 200 25
FH 1000 20 15 25 20
4000 25 15 25 20
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ence of EAD at the cellular level. For example, there were instances with
EAD in the action potential in the 2D model that did not result in ar-
rhythmia in the simulated ECG. It can be seen in Fig. 6C, where applica-
tion of 20 nM dofetilide caused EAD in the ﬁrst pulse, but not
arrhythmia. The abnormal recording in ECG was due to hyperacute T
wave. Therefore, EAD in the 2Dmodel could produce abnormal record-
ing in ECG, but did not always result in arrhythmia. These results also
highlight the importance of tissue model for predicting drug
proarrhythmia and it is believe that in silico study using the 2D model
could provide useful information on drug potential for TdP-like
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Fig. 7.Differential effects of dofetilide on QTc, APD90, and APD90 dispersion in the non-FH and FHmodels. Simulated effects of dofetilide on QTc change in the 2Dmodel (A), APD90 change
in the 2D model (B), and APD90 change in the 0D model (C). Green, blue, and red ﬁlled circles denote Endo, M, and Epi, respectively, in the non-FH model. Green, blue, and red open
triangles denote Endo, M, and Epi, respectively, in the HF model. Simulated effects of dofetilide on APD90 dispersion in the 2D model (D), and APD90 dispersion in the 0D model (E).
The APD90 dispersion is deﬁned as the difference of APD90 between Endo and M layers, or between Epi and M layers. Green and red ﬁlled circles denote APD90 dispersion between
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Epi and M layers, respectively, in the FH model.
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concentration in the experimental study.
4.4. Limitations
In the present study, we used a 2Dmodel rather than a 3Dmodel as
transmural ventricular wedge preparation. Although we need to show
equivalence between these two models, we believe that our 2D model
is one of the most cost- and time-effective approaches. We constructed
a FHmodel based on selected experimental data and showed the poten-
tial use of FH model for predicting preclinical drug candidates’ cardiac
safety. However, we should consider the signiﬁcant effect of variability
in parameterization of such a complex model, particularly FH simula-
tion as a tool to evaluate drugs effects in patients. Because of the avail-
ability of numerous FH experimental data as reported by Elshrif et al.
(2014), we constructed our FH model based on ORd model as a bottom
up approach and referred to clinical data as a top down approach. There
are several possibilities of the diseased model, even if it based on
experimenal studies of human heart.
For simulation study, we need to know not only the effects of drugs
on various cardiac ion channels, but also drug pharmacokinetics for ac-
curate prediction of drug cardiac safety. Although it is not easy to collect
all useful in vitro data for simulation at preclinical stage, it is critical to
have accurate evaluation of drug cardiac safety. Determination of “use-
ful data for simulation” remains also an important part for future prog-
ress of in silico studies.5. Conclusions
Our 2D transmural ventricular wedge preparation model faithfully
reproduced drug-induced QTc changes and arrhythmogenic effects in
the non-FH and FH. Especially, the 2D model well reproduced QTc
change reported in the IQ-CSRC prospective study. Clearly the initial ap-
proach within CiPA will be a single cell model. This is a logical starting
point and may still provide a relevant model for proarrhythmia risk de-
tection as long as model performance is qualiﬁed and validated. After
all, the 0D and 2D models are also just models of actual physiology
and thus still subject to potential shortcomings in translation. Nonethe-
less, this study made a compelling case for a 2D model as a signiﬁcant
improvement over a single cell model and as a reasonable substitute
for a currently impractical whole heart in silico model. The 2D model
provides a good approximation of whole heart proarrhythmia rather
than relying solely on cellular arrhythmia. Therefore, our in silico ap-
proach would provide valuable insights into the prediction of drug car-
diac safety.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.vascn.2016.08.007.Acknowledgment
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